$2.34
-0.1-4.10%
At Close: -
$2.34
00.00%
After Hours: 4:03 PM EDT
15 minutes delayed
Akoya Biosciences
AKYANASDAQ
Akoya Biosciences (NASDAQ:AKYA) Stock, Analyst Ratings, Price Targets, Predictions
Akoya Biosciences Inc has a consensus price target of $7.72, established from looking at the 26 latest analyst ratings. The last 3 analyst ratings were released from Morgan Stanley, Canaccord Genuity, and BTIG on June 3, 2024, May 14, 2024, and May 14, 2024. With an average price target of $5.33 between Morgan Stanley, Canaccord Genuity, and BTIG, there's an implied 127.92% upside for Akoya Biosciences Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
Canaccord Genuity
BTIG
JP Morgan
UBS
1calculated from analyst ratings
Analyst Ratings for Akoya Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/03/2024 | Buy Now | 70.94% | Morgan Stanley | Tejas Savant | $8 → $4 | Maintains | Overweight | Get Alert |
| 05/14/2024 | Buy Now | 156.41% | Canaccord Genuity | Kyle Mikson | $10 → $6 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 156.41% | BTIG | Mark Massaro | $9 → $6 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | 327.35% | JP Morgan | Rachel Vatnsdal | $12 → $10 | Maintains | Overweight | Get Alert |
| 03/05/2024 | Buy Now | 327.35% | Canaccord Genuity | Kyle Mikson | → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2024 | Buy Now | 220.51% | UBS | John Sourbeer | $7 → $7.5 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | — | Guggenheim | Subbu Nambi | — | Initiates | → Neutral | Get Alert |
| 11/13/2023 | Buy Now | 241.88% | Piper Sandler | David Westenberg | $11 → $8 | Maintains | Overweight | Get Alert |
| 11/13/2023 | Buy Now | 284.62% | Stephens & Co. | Mason Carrico | $14 → $9 | Maintains | Overweight | Get Alert |
| 10/24/2023 | Buy Now | 241.88% | Morgan Stanley | Tejas Savant | $15 → $8 | Maintains | Overweight | Get Alert |
| 10/16/2023 | Buy Now | 370.09% | Piper Sandler | David Westenberg | $14 → $11 | Maintains | Overweight | Get Alert |
| 10/12/2023 | Buy Now | 199.15% | UBS | John Sourbeer | $12 → $7 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 541.03% | Morgan Stanley | Tejas Savant | $16 → $15 | Maintains | Overweight | Get Alert |
| 08/08/2023 | Buy Now | 583.76% | Stephens & Co. | Mason Carrico | → $16 | Reiterates | Overweight → Overweight | Get Alert |
| 05/10/2023 | Buy Now | 583.76% | Morgan Stanley | Tejas Savant | $17 → $16 | Maintains | Overweight | Get Alert |
| 03/21/2023 | Buy Now | 583.76% | Stephens & Co. | Mason Carrico | → $16 | Reiterates | → Overweight | Get Alert |
| 03/08/2023 | Buy Now | 626.5% | Morgan Stanley | Tejas Savant | $18 → $17 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | 711.97% | Capital One | Timothy Chiang | → $19 | Initiates | → Overweight | Get Alert |
| 10/06/2022 | Buy Now | 583.76% | Stephens & Co. | Mason Carrico | → $16 | Initiates | → Overweight | Get Alert |
| 08/17/2022 | Buy Now | 626.5% | Piper Sandler | David Westenberg | $14 → $17 | Maintains | Overweight | Get Alert |
| 06/22/2022 | Buy Now | 583.76% | BTIG | Mark Massaro | → $16 | Initiates | → Buy | Get Alert |
| 05/16/2022 | Buy Now | 498.29% | Piper Sandler | David Westenberg | $18 → $14 | Maintains | Overweight | Get Alert |
| 05/09/2022 | Buy Now | 669.23% | Morgan Stanley | Tejas Savant | $19 → $18 | Maintains | Overweight | Get Alert |
| 03/18/2022 | Buy Now | 669.23% | Piper Sandler | David Westenberg | $23 → $18 | Maintains | Overweight | Get Alert |
| 03/15/2022 | Buy Now | 711.97% | Morgan Stanley | Tejas Savant | $20 → $19 | Maintains | Overweight | Get Alert |
| 02/15/2022 | Buy Now | 754.7% | Morgan Stanley | Tejas Savant | $24 → $20 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Akoya Biosciences (AKYA) stock?
The latest price target for Akoya Biosciences (NASDAQ:AKYA) was reported by Morgan Stanley on June 3, 2024. The analyst firm set a price target for $4.00 expecting AKYA to rise to within 12 months (a possible 70.94% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Akoya Biosciences (AKYA)?
The latest analyst rating for Akoya Biosciences (NASDAQ:AKYA) was provided by Morgan Stanley, and Akoya Biosciences maintained their overweight rating.
When was the last upgrade for Akoya Biosciences (AKYA)?
There is no last upgrade for Akoya Biosciences
When was the last downgrade for Akoya Biosciences (AKYA)?
There is no last downgrade for Akoya Biosciences.
When is the next analyst rating going to be posted or updated for Akoya Biosciences (AKYA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akoya Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akoya Biosciences was filed on June 3, 2024 so you should expect the next rating to be made available sometime around June 3, 2025.
Is the Analyst Rating Akoya Biosciences (AKYA) correct?
While ratings are subjective and will change, the latest Akoya Biosciences (AKYA) rating was a maintained with a price target of $8.00 to $4.00. The current price Akoya Biosciences (AKYA) is trading at is $2.34, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.